^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FSIP2 mutation

    i
    Other names: Fibrous Sheath Interacting Protein 2, Fibrous Sheath-Interacting Protein 2, FLJ34780, SPGF34, FSIP2
    Entrez ID:
    401024
    over4years
    Combination of 35-Gene Mutation Profile and Radiotherapy Dosimetry Predicts the Therapeutic Outcome of Definitive Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma. (PubMed, Front Oncol)
    Our cohort showed higher MUC17 (79.5% vs. 5.7%), FSIP2 (18.2% vs. 6.2%), and SYNE1 (38.6% vs. 11.0%) mutation rates and lower TP53 (38.6% vs. 68.7%) mutation rates than the ESCC cohorts from The Cancer Genome Atlas. In conclusion, by using a combination of a 35-gene mutation profile and radiotherapy dosimetry, mutations in FSIP2 and SYNE1 as well as lung V30 were identified as potential predictors for developing a prediction model for clinical outcomes in patients with ESCC administered definitive CCRT.
    Clinical • Journal
    |
    TP53 (Tumor protein P53) • FSIP2 (Fibrous Sheath Interacting Protein 2) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1)
    |
    TP53 mutation • FSIP2 mutation